ArticleBMC veterinary research2025
Serotyping and antimicrobial resistance of Actinobacillus pleuropneumoniae isolates from fattening pigs in Poland from 2019 to 2024.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Actinobacillus pleuropneumoniae - today's perspective on advances and challenges (2017- 2026).BMC veterinary research · 2026Review
- Epidemiological Analysis of Environmental Factors Affecting Porcine Pleuropneumonia in a Herd Endemic forPathogens (Basel, Switzerland) · 2026Article
- A novel tulathromycin oil suspension injection: preparation, characterization, and pharmacokinetics in goats.BMC veterinary research · 2026Article
- Serotypes, MIC-Based Antimicrobial Susceptibility, and Genotypic Diversity ofMicroorganisms · 2026Article
- A Triplex Real-Time PCR Assay for Simultaneous Detection ofTransboundary and emerging diseases · 2026Article
- Atypical multidrug-resistant serotype 1Frontiers in veterinary science · 2026Article
- Characterization ofFrontiers in veterinary science · 2026Article
- Synergistic effect and resistance prevention activity of antimicrobial peptide MPX with Tulathromycin againstFrontiers in microbiology · 2026Article
- Evaluating the Immunogenic Potential of ApxI and ApxII fromVeterinary sciences · 2025Article
- Genome analysis of Actinobacillus pleuropneumoniae strain APPFJLYC01 reveals multidrug resistance and high virulence potential.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActinobacillus pleuropneumoniae is a prevalent respiratory pathogen causing substantial economic losses in swine production worldwide. The bacterium's ability to rapidly develop antimicrobial resistance (AMR) poses a significant challenge to effective treatment and control. In Poland, limited data on A. pleuropneumoniae serotype distribution and AMR patterns hinder evidence-based treatment strategies. This study examined the serotype diversity and AMR patterns of A. pleuropneumoniae isolates from porcine pleuropneumonia outbreaks in northeastern Poland between 2019 and 2024, providing crucial information for regional veterinary practices and antimicrobial stewardship efforts.
resultsAnalysis of 119 isolates from 67 farms demonstrated the predominance of serotype 2 (65.5%), followed by serogroups 3, 6, 8 (18.5%) and 1, 9, 11 (15.1%). This distribution differs from recent trends in other European countries, suggesting regional epidemiological variations. High resistance rates were observed for tylosin (55.5%), gentamicin (36.1%), doxycycline (32.8%), and sulfamethoxazole/trimethoprim (26.1%). Multidrug resistance fluctuated between 14.3% and 21.9% over the study period, with no clear linear trend. From 2022 onwards, strains exhibiting resistance to seven or more antimicrobials, including cephalosporins, emerged, marking a significant shift in resistance profiles. Temporal analysis revealed diverse resistance patterns, with significant increases in some antimicrobials (e.g., sulfamethoxazole/trimethoprim, p = 0.001) and stability in others (e.g., tetracycline, p = 0.890). Notably, several antimicrobials, including florfenicol and colistin, maintained 100% efficacy against all isolates throughout the study period.
conclusionsThe findings highlight the dynamic nature of AMR development in A. pleuropneumoniae and underscore the need for ongoing surveillance in the region. The emergence of highly resistant strains, particularly those resistant to cephalosporins, raises concerns about future treatment options. These results can guide evidence-based treatment strategies and enhance antimicrobial stewardship efforts in regional swine production. Furthermore, the study emphasizes the importance of local AMR data in guiding antimicrobial use policies and the need for a coordinated approach to combat AMR in veterinary medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.